Transcatheter Aortic Valve Replacement With the SAPIEN 3 A New Balloon-Expandable Transcatheter Heart Valve by Binder, Ronald K. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 6 , N O . 3 , 2 0 1 3
© 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 2 . 0 9 . 0 1 9Transcatheter Aortic Valve Replacement
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A New Balloon-Expandable Transcatheter Heart Valve
Ronald K. Binder, MD,* Josep Rodés-Cabau, MD,† David A. Wood, MD,*
Michael Mok, MD,† Jonathon Leipsic, MD,* Robert De Larochellière, MD,†
Stefan Toggweiler, MD,* Eric Dumont, MD,† Melanie Freeman, MBBS,*
Alexander B. Willson, MBBS,* John G. Webb, MD*
Vancouver, British Columbia, and Quebec City, Quebec, Canada
Objectives The aim of this study was to demonstrate the ﬁrst-in-human feasibility and short-term
clinical outcomes with a new balloon-expandable transcatheter heart valve (THV).
Background The SAPIEN 3 (S3) THV incorporates a paravalvular sealing system, an active 3-dimen-
sional coaxial positioning catheter, and is compatible with a 14-F expandable sheath.
Methods The S3 THV was implanted in 15 patients with symptomatic severe aortic stenosis via
femoral arterial access. Multidetector computed tomography before and after valve implantation
allowed assessment of a novel annular area sizing algorithm. Clinical and echocardiographic data
were obtained at baseline, discharge, and 30 days.
Results All 15 device implants were successful. Multidetector computed tomography estimated an
aortic annular area of 4.9  0.4 cm2, predicting 9.7  6.9% THV oversizing. Post-transcatheter aortic
valve replacement multidetector computed tomography showed consistently symmetrical and circu-
lar THVs. Aortic valve area increased from 0.7  0.2 cm2 to 1.5  0.2 cm2 (p  0.001), and mean
transaortic gradient decreased from 42.2  10.3 mm Hg to 11.9  5.3 mm Hg (p  0.001). No pa-
tient had more than mild paravalvular aortic regurgitation. Hospital discharge occurred at a median
of 3 (range 2 to 12) hospital days. At 30 days there were no deaths, strokes, vascular complications,
bleeds, or transfusions, although 1 patient (6.7%) required a new pacemaker. All patients were in
New York Heart Association functional class I or II.
Conclusions The S3 THV and delivery system might facilitate fully percutaneous implantation in a
broader range of patients with the potential for more accurate positioning and less paravalvular
regurgitation. (J Am Coll Cardiol Intv 2013;6:293–300) © 2013 by the American College of
Cardiology Foundation
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294Transcatheter aortic valve replacement (TAVR) has be-
come a generally accepted option for symptomatic severe
aortic stenosis in “inoperable” patients (1,2) and is
noninferior to surgical aortic valve replacement in “high-
risk operable” patients (3,4). After the first-in-human
TAVR over 10 years ago (5), the procedure continues to
be refined (6). Current efforts focus on minimizing access
site complications, stroke risk, paravalvular regurgitation,
and atrioventricular block while facilitating accurate po-
sitioning. To some extent these issues will be addressed
by new transcatheter heart valves (THV) and delivery
systems. We report the first-in-human experience with a
new balloon-expandable THV, the SAPIEN 3 (S3)
(Edwards Lifesciences, Inc., Irvine, California), which
incorporates features intended to reduce vascular compli-
cations, increase paravalvular sealing, and enhance ease of
positioning.
Methods
Transcatheter aortic valve replace-
ment with the S3 was performed
in 15 patients with symptomatic,
severe aortic stenosis at 2 centers
(St. Paul’s Hospital, Vancouver,
Canada and the Quebec Heart
and Lung Institute, Quebec, Can-
ada) between January and June
2012. Patients were considered
at increased risk for surgery by a
multidisciplinary team, includ-
ing cardiac surgeons and cardi-
ologists, because of age, frailty,
comorbidities, or technical issues
(e.g., porcelain aorta, adherent
grafts). All patients gave written informed consent for
prospective data acquisition approved by the local ethics
committee. Short-term clinical outcomes were reported
according to the Valve Academic Research Consortium
guidelines (7). Patients underwent pre-procedural aortic
root, coronary, and iliofemoral angiograms, transthoracic
echocardiography (TTE), and multidetector computed to-
mography (MDCT). The THV sizing incorporated
MDCT annular area assessment according to the Vancou-
ver computed tomography sizing guidelines (Table 1).
Annular area oversizing was calculated as: (THV nominal
area/annular area  1)  100. Patients underwent intra-
nd peri-procedural transesophageal echocardiography
TEE). TTE was performed in all patients before discharge.
The MDCT was repeated post-implant. The THV
eometry was assessed by measuring long- and short-axis
iameters from cross-sectional images of the inflow, out-
ow, and midportion of the stent frame. Eccentricity was
Abbreviations
and Acronyms
CT  computed tomography
MDCT  multidetector
computed tomography
PAR  paravalvular aortic
regurgitation
TAVR  transcatheter aortic
valve replacement
TEE  transesophageal
echocardiography
THV  transcatheter heart
valve
TTE  transthoracic
echocardiographyefined as (1  short diameter/long diameter)  100, with iTHV considered circular when eccentricity was10% (8).
he THV area was assessed by tracing the external margins
f the stent at the inflow, outflow, and midportion of the
tent frame. Expansion was defined as (THV external
rea/nominal THV area)  100, with 90% expansion
onsidered under-expanded.
Clinical and echocardiographic follow-up were obtained
t 30 days. All data were prospectively collected in a
edicated database.
Device. The S3 THV (Fig. 1) incorporates a stent and
leaflet design that allows for crimping to a reduced profile as
compared with the predicate SAPIEN and SAPIEN XT
devices (Table 2). As with these earlier devices, the inflow of
the S3 is covered by an internal polyethylene terephthalate
skirt. However, the S3 incorporates an additional outer
polyethylene terephthalate cuff to enhance paravalvular
sealing. This sealing cuff has no filling and functions like
a parachute by bulging outward (Fig. 2). At the time of
this study the S3 THV was available in a 26-mm (fully
expanded diameter) version. The height of the crimped
frame is 28 mm, shortening 8 mm to a height of 20 mm
when deployed.
Delivery system. The delivery system (Commander)
Figs. 2 and 3) incorporates a nose cone tipped inner
alloon catheter on which the prosthesis is crimped and an
uter deflectable flex catheter. An attached handle (Fig. 2)
Table 1. CT Sizing Guidelines Demonstrating Valve Selection and
Percentage of Aortic Annular Area Oversizing on the basis of CT
Annular Area and Valve Size
Annular Area (mm2) Percent Oversizing
400 NR
410 29.5
420 26.4
430 23.5
440 20.7
450 18.0
460 15.4
470 13.0
480 10.6
490 8.4
500 6.2
510 4.1
520 2.1
530 0.2
540 NR
Percentage of annular oversizing calculated by nominal external valve area/annular area. The
lower and upper limits for annular oversizing are 0% and 30%, respectively, where the upper limit
would represent 0% oversizing with the anticipated next largest (29 mm) valve. The target
amount of annular oversizing is 5% to 15%. If oversizingby 20% to 30% is anticipated, underfilling
the deployment balloon by 1 to 3 ml or undersizing should be considered. Given the nominal
deploymentballoon volumeof 22ml for the 26-mmSAPIEN3, thiswould translate into 5% to15%
balloon underfilling.
CT computed tomography; NR not recommended.ncorporates a rotating wheel used to deflect the flex
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295catheter tip, a flex indicator that indicates the degree of tip
articulation, a fine adjustment wheel for fine alignment of
the THV during valve alignment, a balloon lock knob to
secure the balloon catheter to the flex catheter, and a flush
port. The balloon catheter contains radio-opaque valve
alignment markers, defining the valve alignment position
and working length of the balloon. A central radio-opaque
marker in the balloon assists in valve positioning. The
delivery system allows for advancing or retracting the valve
several millimeters up or down within the annulus by
rotating the fine alignment wheel.
Sheath. The system uses a 14-F expandable sheath (eSheath,
dwards Lifesciences, Inc.). The low-profile sheath is
ntended to reduce the potential for arterial injury during
ntroduction but can transiently expand to accommodate
assage of the compressed valve and then return to its lower
rofile diameter. The working length of the sheath is 36
m (Fig. 4, Table 3).
Procedure. The TAVR was performed under general anes-
hesia with fluoroscopic and TEE guidance (Fig. 5). Pa-
ients were pre-medicated with aspirin and clopidogrel. A
4-F eSheath was introduced into the common femoral
Figure 1. The SAPIEN 3 Valve
This transcatheter heart valve comprises a balloon-expandable, radio-
opaque, cobalt chromium frame; a trileaﬂet bovine pericardial tissue valve;
and polyethylene terephthalate fabric. The inﬂow of the valve is covered
by an outer polyethylene terephthalate cuff, which enhances paravalvular
sealing. The height of the 26-mm SAPIEN 3 (Edwards Lifesciences, Inc.,
Irvine, California) is expanded 20 mm and crimped 28 mm, shortening
8 mm during deployment. The nominal external area of the fully expanded
26-mm SAPIEN 3 stent is 5.31 cm2.
Table 2. Evolution of Balloon-Expandable Transcatheter Heart Valves
Features
SAPIEN Model 9000T
(26 mm)
Crimped proﬁle 8.3 mm
Frame height (expanded) 16.1 mm
Frame height (crimped) 18.1 mm
Frame shortening (deployment) 2 mm
Delivery system RetroFlex3
Sheath proﬁle (internal diameter unexpanded) 24-FIndicated vessel size 7 mmrtery. Balloon aortic valvuloplasty was performed under
apid ventricular pacing. The delivery catheter was advanced
ver an Amplatz extra stiff 0.035-inch guidewire (Cook,
nc., Bloomington, Indiana) into the left ventricle. Accurate
ositioning of the THV was ascertained by aortic root
ngiograms with a pigtail catheter and by TEE guidance.
inal deployment was documented by aortic root angiogram
nd TEE. The femoral access site was closed as per local
ractice either percutaneously (Perclose ProGlide, Abbott,
nc., Abbott Park, Illinois) (10 Vancouver patients) or
urgically (5 Quebec City patients). Patients were moni-
ored for at least 48 h and discharged to continue on a
egimen of low-dose aspirin (81 mg) and 3 months of daily
SAPIEN XT Model 9300TFX
(26 mm)
SAPIEN 3 Model 9600TFX
(26 mm)
8 mm 6.7 mm
17.2 mm 20mm
20.1 mm 28mm
2.9 mm 8mm
NovaFlex Commander
18-F 14-F
Figure 2. Features of the Delivery System
The handle contains a ﬂexion indicator (rotating the blue wheel creates
ﬂexion), depicting to what degree or not the catheter is ﬂexed, a ﬁne
adjustment wheel for ﬁne adjustment of the transcatheter heart valve dur-
ing valve alignment (black wheel), and a balloon lock knob (white wheel)
to secure the balloon catheter to the ﬂex catheter. Once the native valve is
crossed, alignment of the crimped transcatheter valve in the aortic annulus
is achieved by rotating the ﬁne adjustment wheel at the back of the han-
dle (white arrows on black wheel). Before deployment, the position of
the valve can be precisely changed millimeter by millimeter more aortic or
ventricular without having to push or pull the catheter. The radio-opaque
marker in the center of the crimped valve indicates the middle of the
deployment balloon. The valve is ﬂanked by 2 small markers, which assist
in aligning the valve on the balloon. The 3 radio-opaque markers (in a row)
proximal to the valve indicate to where the ﬂex catheter has to be pulled
back to fully expose the deployment balloon.FX6.5 mm 6.0 mm
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296clopidogrel (75 mg). If oral anticoagulation was indicated, it
was continued as monotherapy.
Statistical analysis. All analyses were performed with SPSS
software (version 17, SPSS, Inc., Chicago, Illinois). Con-
tinuous variables are expressed as mean values  SD.
Categorical variables are described by frequencies and per-
centages. Comparisons of continuous variables were per-
formed by the t test. All statistical tests were 2-tailed, and a
alue of p  0.05 was considered statistically significant.
esults
Patients. Baseline clinical characteristics are outlined in
Table 4.
Clinical outcomes. All patients underwent successful device
mplantation. There were no minor or major vascular
omplications and no minor or major bleeds. Post-dilation
as not necessary, and no patient required implantation of
second THV. In 1 patient with very tortuous iliac arteries
he 14-F eSheath kinked, and the procedure was subse-
uently performed with a 16-F eSheath. New left bundle
ranch block developed in 3 patients, becoming permanent
n 1 (6.7%). A pacemaker was implanted in 1 patient (6.7%)
ue to persistent second-degree atrioventricular block. All
atients were discharged home after a median of 3 (range 2
o 12) hospital days.
At 30-day follow-up there were no myocardial infarc-
ions, minor or major strokes, transient ischemic attacks,
Figure 3. Flexibility of the New and Previous Delivery Catheters
The ﬂexibility of the Commander (dark blue) is higher than the NovaFlex
(light blue), which assist in coaxial alignment of the transcatheter heart
valve. The delivery systems include a short tapered tip at the distal end of
the delivery system to facilitate crossing the native valve and the balloon
catheter for deployment of the transcatheter heart valve.inor or major bleeds, minor or major vascular complica-ions, repeat valve procedures, hospital readmissions, or
eaths, although the Society of Thoracic Surgeons Pre-
icted Risk of Mortality was 5.4  3.2%. All patients were
n New York Heart Association functional class I or II.
Echocardiogram. Mean transaortic gradient was reduced
from 42.2  10.3 mm Hg to 13.0  5.1 mm Hg at
discharge (p  0.001) and 11.9  5.3 mm Hg at 30 days.
Aortic valve area increased from 0.7  0.2 cm2 to 1.5  0.2
m2 at discharge (p  0.001) and 1.5  0.3 cm2 at 30 days.
Paravalvular aortic regurgitation (PAR) as assessed by TTE
at discharge was none in 2 (13%), trivial in 9 (60%), and
mild in 4 (27%) patients. No patient had more than mild
PAR assessed by intra-procedural TEE, pre-discharge
TTE, or 30-day follow-up TTE.
MDCT annulus evaluation. The aortic annular diameter
measured 23.1  1.5 mm on TTE, 23.1  0.8 mm on
TEE, and 24.2 1.7 mm on MDCT (mean of the MDCT
short and long axis). Baseline aortic annulus dimensions are
shown in Table 3.
The MDCT estimated an aortic annular area of 4.9 0.4
cm2 with the THV oversized 9.7  6.9% by area. However,
2 of these THVs were actually smaller than the MDCT
estimated annular area in the patients, 1 of whom had a very
eccentric bicuspid valve (1 of 15 patients had a bicuspid
valve). Despite modest undersizing (4.8% and 1.7%), both
had only trivial leaks after THV implantation.
Post-TAVR MDCT showed that THVs were consis-
tently symmetrical and circular (Fig. 6). Mean THV eccen-
tricity was 2.9  2.1%, 2.3  2.5%, and 2.6  1.7% at the
inflow, midportion, and outflow, respectively. The outflow
of the S3 stent frame was located 0.8  2.2 mm below the
left main, and the inflow extended 4.9  2.5 mm below the
aortic annulus. All valves but 1 were fully expanded (mean
THV area expansion was 102  7%, 101  6%, and 106 
6% at the inflow, midportion, and outflow, respectively).
The “underexpanded” THV was expanded 89%, 84%, and
91% at the inflow, midportion, and outflow, respectively
(failing to meet the 90% expansion threshold for “com-
plete” expansion). It had been implanted into the smallest
Figure 4. The Principle of an Expandable Sheath
The expandable sheath temporarily enlarges by unfolding to allow entry of
the device (expanded outer diameter 8 mm for the SAPIEN 3 26-mm valve)
and subsequently recoils to its reduced proﬁle as the transcatheter heart
valve passes. This expansion minimizes the force required to insert and
pass the delivery system and transcatheter heart valve through the sheath,
while maintaining a reduced proﬁle in comparison with standard, nonex-
pandable introducer sheaths.
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297annulus of the cohort (21% oversizing of the native annulus
area 4.4 cm2 with 30% eccentricity); however, the valve area
n TTE was 1.4 cm2 (mean gradient 13 mm Hg), and the
HV was circular on MDCT (eccentricity 7%, 4%, and 5%
t the inflow, midportion, and outflow, respectively).
iscussion
We report the first-in-human experience with a new low-
profile, balloon-expandable valve. Transcatheter aortic valve
replacement was successful in all patients. At 30-day follow-
up, there were no deaths, repeat hospital stays, myocardial
infarctions, strokes, or vascular or bleeding complications.
Clinical and hemodynamic outcomes were excellent. The
advantages of the S3—compared with the Cribier Edwards,
Figure 5. Implantation Sequence
To determine the optimal, perpendicular implant angle, where all 3 cusps are
formed from a rotational C-arm angiogram (A). The implant angle was conﬁrm
(C), after crossing the valve. The alignment of the transcatheter heart valve in
Table 3. Comparison of Sheath Sizes
14-F eSheath
Recommended valve SAPIEN 3 26 m
Sheath ID Unexpanded 4.7 mm
Sheath OD Unexpanded 6 mm
Expanded with valve 8 mm
Recommended minimum artery
diameter
6 mm
Sheath OD/vessel ID (SFAR) Unexpanded 1.0
Expanded with valve 1.33
eSheath (Edwards Lifesciences, Inc., Irvine, California).
ID internal diameter; OD outer diameter; SFAR sheath to femoral artery ratio on the basisdeployed under rapid ventricular pacing (F). Paravalvular sealing (G) and ﬁnal positiSAPIEN (currently approved for clinical use in the United
States), and SAPIEN XT THVs—are its lower profile
(Table 1), facilitated positioning, and the paravalvular seal-
ing cuff. Clinical trials of the S3 device and delivery system
are anticipated to begin later this year.
Vascular complications. Vascular complications have been a
ajor cause of morbidity and mortality after TAVR (1,9). A
trong predictor of vascular complications is the ratio of the
uter diameter of the sheath to the minimal lumen diameter
f the access artery (10). The ability to introduce the S3
HV through a 14-F expandable sheath is likely to translate
nto better outcomes and might facilitate transfemoral
AVR in patients previously considered unsuitable for
emoral access (10). The absence of vascular complications
tely depicted in 1 line, a 3-dimensional aortic root reconstruction was per-
a conventional angiogram (B). A balloon aortic valvuloplasty was performed
rtic annulus (D) was conﬁrmed by an angiogram (E). The SAPIEN 3 was
16-F eSheath 18-F eSheath 20-F eSheath
SAPIEN XT 20 mm 23 mm SAPIEN XT 26 mm SAPIEN XT 29 mm
5.3 mm 6mm 6.7 mm
6.7 mm 7.2 mm 8mm
8.9 mm 8.9 mm 9.9 mm
6mm 6.5 mm 7mm
1.12 1.11 1.14
1.48 1.37 1.41
mmended minimum artery diameter.separa
ed by
the aomon (H) were assessed.
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298in this feasibility study is consistent with the possibility of a
reduction in vascular complications, improved outcomes in
general, and potential application in a broader spectrum of
patients.
PAR. Paravalvular aortic regurgitation after TAVR has been
ssociated with increased mortality (11). Although an asso-
iation of mild PAR with mortality was found in the 2-year
nalysis of the PARTNER (Placement of Aortic Transcath-
ter Valves) 1A trial (2), a cause-and-effect relationship was
ot established. In the PARTNER 1A and 1B trials core
aboratory analysis reported moderate or severe PAR at 30 days
n 12.2% and 11.8%, respectively (1,3). In the present study no
atient had moderate or severe PAR. Paravalvular aortic
egurgitation was absent or trivial in 73% of patients and mild
n the remainder. Possible reasons for this low PAR rate
nclude: 1) the outer polyethylene terephthalate sealing cuff,
hich enhances paravalvular sealing; 2) more accurate posi-
ioning; and 3) improved sizing with adjunctive MDCT.
Sizing recommendations. It is known that undersizing
THVs is a potential cause for PAR and device embolization;
Table 4. Baseline Characteristics (N15)
Age (yrs) 80.3 11.2
Male 15 (100%)
Diabetes 3 (20%)
Height (cm) 174.1 5.7
Weight (kg) 79.3 13.6
Prior CABG 6 (40%)
COPD 5 (33%)
Prior pacemaker 2 (13%)
Porcelain aorta 1 (7%)
STS PROM score (%) 5.4 3.2
NYHA pre-TAVR
I 0 (0%)
II 5 (33%)
III 9 (60%)
IV 1 (7%)
GFR (ml/min.) 59.6 24.0
Hemodialysis 1 (7%)
TEE aortic annulus diameter (mm) 23.1 0.8
TTE aortic annulus diameter (mm) 23.1 1.5
MDCT aortic annulus diameter (mm) 24.2 1.7
MDCT aortic annulus area (cm2) 4.9 0.4
AVA (cm2) 0.7 0.2
Transaortic gradient (mm Hg) 42.2 10.3
LVEF (%) 55.3 9.3
Mitral regurgitation (moderately severe to severe) 1 (7%)
Values are mean SD or n(%).
AVA  aortic valve area; CABG  coronary artery bypass graft; COPD  chronic obstructive
pulmonary disease; GFR  glomerular filtration rate; LVEF  left ventricular ejection fraction;
MDCTmultidetector computed tomography; NYHA New York Heart Association functional
class; STS PROM Society of Thoracic Surgeons predicted risk ofmortality; TAVR transcatheter
aortic valve replacement; TEE transesophageal echocardiography; TTE transthoracic echo-
cardiography.however, this knowledge is balanced by an appreciation thataggressive oversizing might contribute to annular rupture,
coronary obstruction, atrioventricular block, peri-aortic he-
matoma, ventricular septal rupture, or anterior mitral leaflet
injury. Traditional sizing criteria on the basis of single-plane
2-dimensional measurements do not appreciate the consis-
tently oval-shaped anatomy of the aortic annulus (12) (Fig. 7).
Recently, 3-dimensional annular assessments by MDCT
and annulus area-based sizing have been shown to predict
PAR and potentially contribute to appropriate valve
sizing (8).
We routinely used 3-dimensional MDCT annular area
measurements. Sizing guidelines were developed to assure
that THVs were moderately but not excessively oversized
relative to the annular area as assessed by MDCT. A
reduction in PAR was anticipated with the improved
accuracy of positioning and the improved external sealing
cuff with this device. Consequently, it was decided that
relatively modest 5% to 15% area oversizing would be
adequate. In addition it was anticipated that avoiding area
oversizing 20%, by slightly under-filling the deployment
balloon, might reduce the risk of annular injury (Table 1).
With this approach PAR burden was minimal, and annular
injury was not encountered. Specific recommendations with
respect to balloon under-filling will have to await further
evaluation of effects on function and durability.
Positioning. The expanded length of the S3 THV is slightly
greater than the currently available SAPIEN and SAPIEN
XT THVs (Table 2). Although differences are small, this
increase seems to greatly facilitate optimal positioning
within the native aortic valve and annulus. The longer stent
frame also decreases the likelihood of native leaflet tissue
prolapse. In addition the delivery system has several char-
Figure 6. 3-Dimensional Reconstructions of the Transcatheter Heart Valve
Sagittal oblique maximum intensity projection (left) and double oblique
transverse (parallel to the plane of the aortic root) images at the inﬂow,
mid, and outﬂow show the circular, full expansion of the SAPIEN 3
(Online Video 1).
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299acteristics intended to facilitate accurate positioning. In-
creased flexion capabilities facilitate supporting the catheter
within the transverse aorta while engaging the native valve
in a coaxial manner (Fig. 3). From this fixed platform minor
adjustments in the height of the implant can be obtained by
using the fine alignment mechanism (Fig. 2).
It seems that, when deployed in a calcified aortic valve,
the outflow of the stent contacts the native leaflet early, at
which point the outflow of the stent frame is “fixed,” with
the inflow moving up toward this point as the stent frame
shortens. Therefore, we developed the strategy of aligning
the top of the THV and the associated balloon marker with
the tips of the native leaflets and the middle marker with the
plane of the annulus (interpreted as the most basal attach-
ments of the leaflets) (Fig. 6, Online Video 1). With this
approach the THV often appeared too ventricular (in
comparison with standard SAPIEN/SAPIEN XT position-
ing); however, early contact with the native leaflets during
expansion seemed to assure a good final position.
Atrioventricular block. Heart block necessitating permanent
acemaker insertion is a concern after TAVR. The large
bservational UK TAVI (United Kingdom Transcatheter
ortic Valve Implantation) (13) and FRANCE 2 (French
ortic National CoreValve and Edwards) (14) registries,
espectively, reported new pacemaker rates of 24.4% and
4.2% with the CoreValve (Medtronic, Minneapolis, Minne-
ota) device versus 7.4% and 11.5% with the SAPIEN/XT valves.
n this present study only 1 patient (6.7%) required a new
acemaker. Whether the risk of atrioventricular block will
e slightly increased by the greater length of the S3 valve
Figure 7. Appreciation of the Aortic Annulus by Multidetector Computed T
Double oblique transverse (parallel to the plane of the aortic root) images from
severe aortic stenosis. The annulus is markedly eccentric with signiﬁcant differ
underappreciated with traditional 2-dimensional imaging. The aortic annular a
systole at maximum valve opening.potentially extending the area of contact with the septum)r slightly reduced by more accurate positioning and a lesser
eed for oversizing is speculative.
onclusions
The low-profile S3 transcatheter valve and delivery system
might facilitate fully percutaneous implantation in a broader
range of patients with the potential for more accurate
positioning and less paravalvular regurgitation.
Reprint requests and correspondence: Dr. John G. Webb, St.
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